evenfolio

Chemicals · NSE: CLEAN

Clean Science and Technology

Q2 FY27 earnings and concall highlights

Price as of 16 Nov 2026
707.25−2.31%

Q2 FY27 earnings call · Guided by management

Call held 31 Oct 2026 · Read the filing on NSEFiling

55–60​%Capacity utilisation · HALS · coming few quartersSikchi · Q&A · p. 9
20–25​%Capacity utilisation · Performance Chemical 2 · first yearSikchi · Q&A · p. 9
₹900​CrTotal investment in subsidiarySikchi · p. 4
5–7​%Margin improvement in those HALS products · HALSSikchi · Q&A · p. 9
M.Cap
₹7,517Cr
P/E
32.2×
1Y return
−23.21%
From 52W high
−26.6%

Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.

Share price

Results Q2 FY27, as filed · consolidated · ₹ Cr

Q2 FY27Q2 FY26YoYQ1 FY27QoQ
Revenue299245+22.4%268+11.5%
EBITDA9287+5.7%96-4.5%
EBITDA margin30.8%35.6%-486 bps35.9%-517 bps
PBTProfit before tax7475-0.6%98-23.7%
Net profit5655+0.5%73-24.0%
EPS (₹)5.245.21+0.6%6.90-24.1%

From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures. In Q2 FY27 the filing tags the owners' profit as ₹0 Cr against its own period profit; the period profit less minority interest is shown.

Guidance

Margin · HALS5-7%In-house HALS KSMs could improve margins 5% to 7% in those HALS products
Utilisation · HALS55-60%HALS utilisation at 30-40%, expected to reach 55% to 60% in coming few quarters
Utilisation · Performance Chemical 220-25%Performance Chemical 2 targets 20% to 25% utilisation in its first year
CapexRs 900 CrTotal investment in subsidiary company stands at INR900 crores

More figures from the call

Company · Capex
₹50​CrCapital infusion in subsidiary · H1 FY27
“During the quarter, capital infusion in subsidiary was approximately INR50 crores and INR150 crores in H1 FY27.”
Siddharth Sikchi · Managing Director and Promoterp. 4
hydroquinone, catechol · Capacity
30–35​%Capacity utilisation
“So in hydroquinone, catechol -- Sanjesh, see, right now, we are at about 30%, 35% capacity utilization. And fortunately, all these capacities are currently used for our own captive consumption.”
Siddharth Sikchi · Managing Director and Promoter · Q&Ap. 6
HALS · Capacity
1,000​tonsNew line capacity · April or May
“And now we believe we have to put up a 1,000 ton line, and we will do so and the plant should start by April or May.”
Siddharth Sikchi · Managing Director and Promoter · Q&Ap. 8
HALS · Capacity
12,500​tonsHALS capacity
“HALS capacity as of now is close to 11,500 tons. With this NOR Collaboration Association, we would like to add incremental capacity only in the advanced grade of HALS. So that will take out our overall capacity to close to 12,500 tons.”
Siddharth Sikchi · Managing Director and Promoter · Q&Ap. 10
HALS · Segments
12​%EBITDA margin · H1 FY27
“we will be starting some of the key starting materials for some of these HALS products, which eventually will result in improvement in our gross margin. Put all together, healthy volumes, continuous process improvement and benefits of operational leverage have resulted in EBITDA margin of 12% in the first half of FY27. And during this quarter, we reached a PAT positive.”
Siddharth Sikchi · Managing Director and Promoterp. 3
HALS · Segments
40​%Advanced HALS share of HALS portfolio
“60% is still 770 and 40% is now the advanced HALS. And I think this ratio will keep changing as we move quarter-on-quarter basis.”
Siddharth Sikchi · Managing Director and Promoter · Q&Ap. 8

In short

  1. 01Consolidated revenue was INR295 crores in Q2, up 23% year-on-year.
  2. 02Raw material cost rose to 43.3% of sales from 39.7%, and the cost could not be passed on as Chinese prices stayed low.
  3. 03HALS revenue doubled year-on-year; HALS utilisation is expected to reach 55% to 60% in the coming few quarters.
  4. 04HALS capacity is close to 11,500 tons, to rise to about 12,500 tons with advanced-grade additions.
  5. 05Performance Chemical 2 commercial production is hoped for in Q4 FY27, targeting 20-25% utilisation in year one.
  6. 06Total investment in the subsidiary stands at INR900 crores; little capex is planned now.
  7. 07In-house HALS raw materials could lift margins in those products by 5% to 7%.
  8. 08Barbituric acid has been put on hold due to Chinese pricing.

Capex

Performance Chemical 2: Performance Chemical 2 to be commercialised by Q3 to Q4 FY27

Siddharth Sikchi · Managing Director and Promoter · p. 4
“Performance Chemical 2 will get commercialized by quarter 3 to quarter 4 FY27.”

HALS: Incremental HALS investment not heavy as it adds lines, not a greenfield

Siddharth Sikchi · Managing Director and Promoter · Q&A · p. 8
“So the incremental investment is not too heavy because, see, ultimately, it earlier was a greenfield project.”

Not much capex now; adjacency capex figure to follow Board approval

Pratik Bora · President · Q&A · p. 8
“Arun, not much capex now because Performance Chemicals is largely funded. For the adjacencies of the pipelines, which Siddharth just alluded to, once we have the investment case approved by the Board, we will arrive at the capex number.”

Performance Chemical 2: Performance Chemical 2 commercial production hoped for in Q4, likely Jan or Feb

Siddharth Sikchi · Managing Director and Promoter · Q&A · p. 9
“So the Performance Chemical 2, the deadline, I mean we are hoping really to start the commercial production in Q4, so probably in the month of Jan, Feb.”

Clean Antioxidant 962: No capex for new antioxidant; made within current assets

Siddharth Sikchi · Managing Director and Promoter · Q&A · p. 10
“So, basically it is currently -- we have not put any capex for that. It is being manufactured within our current assets.”

Capacity

light stabilizer: Plans to de-bottleneck and add capacity in some light stabilizer products, plus adjacencies

Siddharth Sikchi · Managing Director and Promoter · Q&A · p. 7
“So we are going to de-bottleneck and we are going to add increased capacities in some of these products and also trying to get in allied or adjacencies, which will be catering to the same customers. So you will see all these products coming up in the next few quarters.”

Segments

HALS: HALS segment revenue grew 2x year-on-year in the quarter

Siddharth Sikchi · Managing Director and Promoter · p. 3
“On the HALS segment, on Y-o-Y basis, the HALS segment grew 2x in revenue during the quarter.”

HALS: H1 FY27 HALS volumes reached 67% of the full previous year's volumes

Siddharth Sikchi · Managing Director and Promoter · p. 3
“To give a little perspective, in H1 FY27, we achieved aggregated volumes of 67% of the total volumes achieved during entire previous financial ye ar.”

HALS: Consolidated EBITDA up 6%, supported by turnaround in CFCL; HALS sales consistent

Siddharth Sikchi · Managing Director and Promoter · p. 4
“The increase in revenue is primarily led by consistent sale of HALS business and consolidated EBITDA grew by 6%, supported by turnaround in CFCL.”

Performance: Sales split: 77% Performance, 14% Pharma Intermediates, 7% FMCG

Siddharth Sikchi · Managing Director and Promoter · p. 4
“The split was 77% Performance, 14% Pharma Intermediates and FMCG was 7%.”

light stabilizer: Management says it is bullish on the light stabilizer segment

Siddharth Sikchi · Managing Director and Promoter · Q&A · p. 7
“So I think we are very bullish on this whole light stabilizer segment.”

Demand

HALS: Company adding new HALS customers and raising wallet share every quarter

Siddharth Sikchi · Managing Director and Promoter · p. 3
“Further, as we speak, we continue to add new customers and increase the wallet share from existing customers every quarter.”

Stand-alone sales up 10% year-on-year, realisation-led; demand steady

Siddharth Sikchi · Managing Director and Promoter · p. 4
“On Y-o-Y comparison, sales grew by 10% during the quarter. The revenue growth was primarily led by improved realization, while volumes were broadly stable. The demand environment continues to be steady.”

hydroquinone, catechol: Small hydroquinone/catechol sales have started in Europe and India

Siddharth Sikchi · Managing Director and Promoter · Q&A · p. 6
“And small sales have picked up in Europe and I think some -- and also something in India.”

Margins and costs

HALS: In-house key starting materials for HALS expected to improve gross margin

Siddharth Sikchi · Managing Director and Promoter · p. 3
“On cost improvement fronts, during the quarter and also in the subsequent quarters, we will be starting some of the key starting materials for some of these HALS products, which eventually will result in improvement in our gross margin.”

Phenol, acetone and methanol 50% to 100% higher year-on-year; coal and freight up

Siddharth Sikchi · Managing Director and Promoter · p. 4
“Key raw materials such as phenol, acetone and methanol were 50% to 100% higher year-on-year alongside an increase in coal and freight costs.”

Consolidated raw material cost rose to 43.3% vs 39.7%; pass-through difficult

Siddharth Sikchi · Managing Director and Promoter · p. 4
“With Chinese prices yet to move up, the pass-through to the customers was difficult. Consequently, the raw material cost rose to 43.3% versus 39.7% on a consolidated basis.”

Stand-alone EBITDA margin 36%, PAT margin 24%; raw material cost rose to 41% from 35%

Siddharth Sikchi · Managing Director and Promoter · p. 4
“EBITDA and PAT margins are at 36% and 24%, translating into EBITDA of INR82 crores and PAT of INR55 crores. Margin moderation was primarily due to high raw material costs, which rose to 41% from 35% in Q1 FY27.”

Price rise not passed on; margin % fell but absolute EBITDA held on volume growth

Siddharth Sikchi · Managing Director and Promoter · Q&A · p. 5
“see, we were not able to pass through the price increase to the customer. So of course, the percentage-wise came down, but on absolute because of the volume growth, we were still able to maintain the absolute number.”

Acquisitions and new business

HALS: CFCL completed trials of advanced-grade HALS; commercial launch expected in H2 FY27

Siddharth Sikchi · Managing Director and Promoter · p. 4
“CFCL has conducted and completed trials for the advanced grade of HALS product. This marks a significant milestone towards the commercial launch of the new product expected to commence in H2 of FY27.”

HALS: Shipments of tested contract product to Europe to start in November or December

Siddharth Sikchi · Managing Director and Promoter · Q&A · p. 6
“Yes, yes. November or December, we'll start shipping this material to Europe.”

barbituric acid: Barbituric acid put on hold as company cannot match Chinese prices

Siddharth Sikchi · Managing Director and Promoter · Q&A · p. 6
“See, basically, we realized that currently, the prices which Chinese are offering, we are not able to offer those prices. So we have kept this product on hold for the moment.”

HALS: HALS adjacency products to start production in the next few quarters

Siddharth Sikchi · Managing Director and Promoter · Q&A · p. 7
“Light stabilizers adjacencies. HALS adjacencies. It's something which we will start producing in the next few quarters.”

Clean Antioxidant 962: New antioxidant now about 500-odd tons, smaller than wanted

Siddharth Sikchi · Managing Director and Promoter · Q&A · p. 10
“Currently, I think we are making just about 500-odd tons, but it's still not as big as we wanted.”

Risks

Chinese prices have not risen enough to pass cost increases to customers

Siddharth Sikchi · Managing Director and Promoter · Q&A · p. 5
“Actually, see, the point is it's market-driven and the prices in China have not risen to the point that we can pass any benefit or any cost increase to the customer.”

barbituric acid: Indian raw materials for barbituric acid almost 3x; no sense to produce now

Siddharth Sikchi · Managing Director and Promoter · Q&A · p. 7
“but the other raw materials which you are buying from India have become almost 3x. So it is not making any sense for us to produce at the moment.”

Input costs stayed high as Middle East conflict kept crude-linked feedstock prices high

Siddharth Sikchi · Managing Director and Promoter · p. 4
“Input costs have remained high during the quarter as the Middle East crisis conflict kept the crude-linked feedstock prices high.”

Other

Exports rose to 73% of stand-alone business from 64% last quarter

Siddharth Sikchi · Managing Director and Promoter · p. 3
“Export sales increased to 73% of the stand-alone business against 64% during the previous quarter.”

Stand-alone revenue up 11% quarter-on-quarter to INR226 crores on higher volumes

Siddharth Sikchi · Managing Director and Promoter · p. 4
“On a sequential basis, revenues improved by 11% to INR226 crores, largely due to higher volume across Performance, Pharma and FMCG.”

Consolidated revenue INR295 crores with EBITDA INR92 crores and PAT INR56 crores

Siddharth Sikchi · Managing Director and Promoter · p. 4
“On a consol basis, company delivered a healthy volume-led growth of 12%, resulting in revenues of INR295 crores on a consolidated basis with EBITDA and PAT margins of INR92 crores and INR56 crores, respectively.”

Consolidated revenue INR295 crores after 12% volume-led growth

Siddharth Sikchi · Managing Director and Promoter · p. 4
“On a consol basis, company delivered a healthy volume-led growth of 12%, resulting in revenues of INR295 crores on a consolidated basis”

Consolidated sales up 23% year-on-year: volume about 10%, realisation 13%

Siddharth Sikchi · Managing Director and Promoter · p. 4
“On Y-o-Y comparison, the sales grew 23% during the quarter. The revenue growth was primarily led by improved volume growth approximately 10% and realization by 13%.”

Sources

Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

Search

Search funds, ETFs, stocks, pages and tools